Chemotherapy's Effectiveness in Young Breast Cancer Patients
Author Information
Author(s): van der Hage Jos A, Mieog J Sven D, van de Vijver Marc J, van de Velde Cornelis JH
Primary Institution: Leiden University Medical Center
Hypothesis
Does hormone receptor status affect the efficacy of adjuvant chemotherapy in young breast cancer patients?
Conclusion
Young patients with hormone receptor-positive tumors benefit less from adjuvant chemotherapy than those with hormone receptor-negative tumors.
Supporting Evidence
- Patients with ER-positive tumors had better overall survival rates compared to those with ER-negative tumors.
- In patients who received chemotherapy, no significant difference in overall survival was found between ER-positive and ER-negative tumors.
- Overall survival rates at 7 years were 82% for ER-positive and 77% for ER-negative patients.
Takeaway
Young women with breast cancer who have hormone receptor-positive tumors may not get much help from chemotherapy, while those with hormone receptor-negative tumors do better with it.
Methodology
The study analyzed data from 480 early-stage breast cancer patients under 41 years old, assessing hormone receptor status and survival outcomes.
Potential Biases
Selection bias may have occurred due to the majority of patients receiving chemotherapy having positive axillary lymph nodes.
Limitations
The analysis used heterogeneous data from different trials and did not account for newer chemotherapy regimens.
Participant Demographics
Patients were early-stage breast cancer patients younger than 41 years, with a mix of hormone receptor-positive and negative statuses.
Statistical Information
P-Value
0.02
Confidence Interval
0.43 to 0.93
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website